Defunct Company
Total Trials
14
As Lead Sponsor
13
As Collaborator
1
Total Enrollment
1,166
NCT00708318
Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Oct 31, 2001
Completion: Jun 30, 2002
NCT00709254
Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects
Start: Dec 31, 2001
Completion: Jan 31, 2002
NCT00794209
Study Evaluating Inhaled AeroLEF Delivered in 4 Aerosol Delivery Devices in Healthy Volunteers
Start: Mar 31, 2003
Completion: May 31, 2003
NCT00791804
Phase II Study of Inhaled AeroLEF for Analgesia After ACL Knee Surgery
Phase: Phase 2
Start: Feb 29, 2004
Completion: Dec 31, 2004
NCT00099281
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
Phase: Phase 3
Start: May 31, 2004
Completion: Jun 30, 2006
NCT00364754
Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
Completion: Jan 31, 2006
NCT00369252
Phase I Study of Nimotuzumab in Solid Tumours
Start: Jun 30, 2005
Completion: Not specified
NCT00286065
Study to Determine Efficacy and Safety of Inhaled AeroLEF in the Treatment of Acute Post-op Pain in Adult Patients Undergoing Elective Orthopedic Surgery
Start: Jan 31, 2006
NCT00364195
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer
Start: Jun 30, 2006
NCT00493857
Study of Nimotuzumab and Irinotecan in Metastatic Colorectal Cancer
Start: Jun 30, 2007
Completion: Dec 31, 2008
NCT00600054
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
Start: Oct 31, 2007
Completion: Dec 31, 2010
NCT00369447
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
Phase: Phase 1/2
Start: Mar 31, 2009
Completion: Jul 31, 2011
NCT00872482
A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases
Start: Apr 30, 2009
NCT01382745
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
Role: Collaborator
Start: Jan 31, 2012
Completion: Jan 31, 2022